GLUE
Monte Rosa Therapeutics, Inc.
There isn't enough reported data to score GLUE yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
GLUE Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
GLUE's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
GLUE PE Valuation
GLUE has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
GLUE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect GLUE's losses to grow, with revenue declining. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
GLUE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.40 | -489% |
| Q2 2026 | -$1.76 | -540% |
| Q1 2026 | -$1.48 | -1333% |
| Q4 2025 | -$0.46 | +$0.52 |
| Q3 2025 | $0.36 | +$2.18 |
| Q2 2025 | $0.40 | +$2.63 |
| Q1 2025 | $0.12 | +$2.63 |
| Q4 2024 | -$0.98 | +$1.65 |
GLUE has swung to a loss: it lost $1.40 per share over the past year, after a profit the year before.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over GLUE on earnings quality, reporting a profit while its opponent remains loss making.
GLUE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $54.4M | +326% |
| Q2 2026 | $9M | -61% |
| Q1 2026 | $4.2M | -95% |
| Q4 2025 | $2.8M | -95% |
| Q3 2025 | $12.8M | +39% |
| Q2 2025 | $23.2M | +394% |
| Q1 2025 | $84.9M | +7882% |
GLUE's revenue is recovering but still below its 2025 peak: $54M last quarter, up 326% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3.6% | +255 points |
| Q2 2026 | -548% | -481 points |
| Q1 2026 | -1188% | -1240 points |
| Q4 2025 | -1788% | -1809 points |
| Q3 2025 | -258% | +30 points |
| Q2 2025 | -67% | +628 points |
| Q1 2025 | 52% | +3336 points |
| Q4 2024 | 21% | N/A |
GLUE's operating margin was −3.6% last quarter, up 255 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over GLUE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over GLUE on profitability, with a higher operating margin.
GLUE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$42.5M | -143% |
| Q2 2026 | -$48.8M | -$12.4M |
| Q1 2026 | -$39.2M | +$7.8M |
| Q4 2025 | -$43.8M | -134% |
| Q3 2025 | $99.8M | +$121.2M |
| Q2 2025 | -$36.4M | -$6.6M |
| Q1 2025 | -$47.1M | -$7.5M |
| Q4 2024 | $128.7M | +361% |
GLUE has burned cash in almost every quarter: −$174M over the past year, against $145M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over GLUE on cash generation, producing positive trailing cash flow while its opponent burns cash.
GLUE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7% | +7.1M shares |
| 1 year | +32% | +26.2M shares |
| 3 years | +118% | +58.8M shares |
| 5 years | +155% | +66.1M shares |
| Available history | +400% | +86.9M shares |
GLUE has 109M diluted shares, up 32% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | $178,000 |
| Q1 2020 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over GLUE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
GLUE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -11.2x | Net Cash |
| Q2 2025 | -2.8x | Net Cash |
| Q1 2025 | -10.4x | Net Cash |
GLUE has more cash than debt.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
GLUE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.0 | Neutral |
| Stochastic | 6.7 | Oversold |
GLUE's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
GLUE PE vs Healthcare Sector
| Metric | GLUE | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
GLUE has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
GLUE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.5 | 11% below |
| 20 week MA | $14.7 | 37% below |
| 50 week MA | $17.0 | 45% below |
| 100 week MA | $11.8 | 21% below |
| 200 week MA | $8.82 | 5.6% above |
GLUE has fallen below most of its moving averages, though it's still 5.6% above its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over GLUE on trend strength, trading above more of its moving averages.
GLUE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $18.9 | $20.9 | +11% |
| 2022 | $20.9 | $7.94 | -62% |
| 2023 | $7.94 | $5.65 | -29% |
| 2024 | $5.65 | $7.06 | +25% |
| 2025 | $7.06 | $17.3 | +145% |
| 2026 YTD | $17.3 | $9.31 | -46% |
GLUE's yearly returns have swung widely, from +145% in 2025 to −62% in 2022. It's down 46% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over GLUE on returns for 2026, with the stronger performance.